DLA Piper is pleased to welcome New York-based Lily Wound as a partner in the firm’s Corporate practice.

Wound represents pharmaceutical, biotechnology, and other life sciences companies in a wide range of complex commercial, corporate, and licensing transactions, including those involving gene therapy, gene editing, engineered cell therapy, and genomic testing. She has worked on some of the most complex life sciences collaborations in the industry and has handled transactions at every stage of the product life cycle.

Some of her notable experience includes: representing an AI-driven biotechnology company focused on RNA splicing diseases in its research collaboration with Bristol Myers Squibb to identify alternative splicing-derived targets for therapeutic development in oncology; advising a clinical-stage gene therapy company in its acquisition of Stelios Therapeutics and its gene therapy programs for rare cardiovascular diseases; and representing a biotechnology company in its research collaboration with a major pharmaceutical company to use its AI-driven tMDP mining and design platform to optimize CAR designs for cellular therapy.

“Lily has extensive experience handling complex matters for life sciences companies. Her deep knowledge and capabilities will be an immediate asset in guiding clients on important licensing matters,” said Andrew Gilbert, US chair of DLA Piper’s corporate practice and global co-chair of the Life Sciences sector.

“We are pleased to welcome Lily, who will help build out our work in a wide range of licensing transactions, as well as bolster our New York presence in the sector,” said Cara Edwards, managing partner of the firm’s New York office. 

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.